Co-Authors
This is a "connection" page, showing publications co-authored by WILLEM OVERWIJK and YARED HAILEMICHAEL.
Connection Strength
3.866
-
Vaccinating with Stem Cells to Stop Cancer. Trends Mol Med. 2018 06; 24(6):524-526.
Score: 0.652
-
Cancer vaccine formulation dictates synergy with CTLA-4 and PD-L1 checkpoint blockade therapy. J Clin Invest. 2018 04 02; 128(4):1338-1354.
Score: 0.644
-
Cancer vaccines: Trafficking of tumor-specific T cells to tumor after therapeutic vaccination. Int J Biochem Cell Biol. 2014 Aug; 53:46-50.
Score: 0.494
-
Peptide-based anticancer vaccines: The making and unmaking of a T-cell graveyard. Oncoimmunology. 2013 Jul 01; 2(7):e24743.
Score: 0.461
-
Persistent antigen at vaccination sites induces tumor-specific CD8? T cell sequestration, dysfunction and deletion. Nat Med. 2013 Apr; 19(4):465-72.
Score: 0.456
-
LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. J Clin Invest. 2022 07 01; 132(13).
Score: 0.218
-
Peptide Vaccine Formulation Controls the Duration of Antigen Presentation and Magnitude of Tumor-Specific CD8+ T Cell Response. J Immunol. 2018 05 15; 200(10):3464-3474.
Score: 0.162
-
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain. Nat Commun. 2017 11 13; 8(1):1447.
Score: 0.158
-
Conference scene: immune effector mechanisms in tumor immunity. Immunotherapy. 2012 Feb; 4(2):141-3.
Score: 0.106
-
Targeted inhibition of inducible nitric oxide synthase inhibits growth of human melanoma in vivo and synergizes with chemotherapy. Clin Cancer Res. 2010 Mar 15; 16(6):1834-44.
Score: 0.093
-
IFN-alpha enhances peptide vaccine-induced CD8+ T cell numbers, effector function, and antitumor activity. J Immunol. 2009 Jun 15; 182(12):7398-407.
Score: 0.088
-
Bempegaldesleukin selectively depletes intratumoral Tregs and potentiates T cell-mediated cancer therapy. Nat Commun. 2020 01 31; 11(1):661.
Score: 0.046
-
Macrophages Facilitate Resistance to Anti-VEGF Therapy by Altered VEGFR Expression. Clin Cancer Res. 2017 Nov 15; 23(22):7034-7046.
Score: 0.039
-
Absence of Grail promotes CD8+ T cell anti-tumour activity. Nat Commun. 2017 08 10; 8(1):239.
Score: 0.039
-
Multifaceted Role of BTLA in the Control of CD8+ T-cell Fate after Antigen Encounter. Clin Cancer Res. 2017 Oct 15; 23(20):6151-6164.
Score: 0.039
-
Soluble interleukin-15 complexes are generated in vivo by type I interferon dependent and independent pathways. PLoS One. 2015; 10(3):e0120274.
Score: 0.033
-
Mouse model for pre-clinical study of human cancer immunotherapy. Curr Protoc Immunol. 2015 Feb 02; 108:20.1.1-20.1.43.
Score: 0.033
-
Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice. Nat Med. 2014 Jun; 20(6):676-81.
Score: 0.031
-
Tumor-expressed inducible nitric oxide synthase controls induction of functional myeloid-derived suppressor cells through modulation of vascular endothelial growth factor release. J Immunol. 2012 Jun 01; 188(11):5365-76.
Score: 0.027
-
Antitumor activity mediated by CpG: the route of administration is critical. J Immunother. 2011 Apr; 34(3):279-88.
Score: 0.025
-
Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res. 2010 May 01; 16(9):2550-61.
Score: 0.023